Predicting Gonadal Germ Cell Cancer in People with Disorders of Sex Development; Insights from Developmental Biology

Leendert H. J. Looijenga 1,*, Chia-Sui Kao 2,† and Muhammad T. Idrees 3,‡

1 Professor Translational Patho-Oncology, Department of Pathology, Lab. for Experimental Patho-Oncology, Erasmus MC-University Medical Center Rotterdam, and Group Looijenga, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
2 Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; ckao2@stanford.edu
3 Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; midrees@iupui.edu
* Correspondence: l.looijenga@erasmusmc.nl or l.looijenga@prinsesmaximacentrum.nl
† Shared last authorship.

Received: 19 August 2019; Accepted: 5 October 2019; Published: 10 October 2019

Abstract: The risk of gonadal germ cell cancer (GGCC) is increased in selective subgroups, amongst others, defined patients with disorders of sex development (DSD). The increased risk is due to the presence of part of the Y chromosome, i.e., GonadoBlastoma on Y chromosome GBY region, as well as anatomical localization and degree of testicularization and maturation of the gonad. The latter specifically relates to the germ cells present being at risk when blocked in an embryonic stage of development. GGCC originates from either germ cell neoplasia in situ (testicular environment) or gonadoblastoma (ovarian-like environment). These precursors are characterized by presence of the markers OCT3/4 (POU5F1), SOX17, NANOG, as well as TSPY, and cKIT and its ligand KITLG. One of the aims is to stratify individuals with an increased risk based on other parameters than histological investigation of a gonadal biopsy. These might include evaluation of defined susceptibility alleles, as identified by Genome Wide Association Studies, and detailed evaluation of the molecular mechanism underlying the DSD in the individual patient, combined with DNA, mRNA, and microRNA profiling of liquid biopsies. This review will discuss the current opportunities as well as limitations of available knowledge in the context of predicting the risk of GGCC in individual patients.

Keywords: germ cell cancer; developmental pathogenesis; individual risk assessment; prediction; disorders of sex development

1. Introduction

Historically, germ cell tumors (GCTs) (independent of anatomical localization), were considered as a highly heterogeneous group of neoplasms, including both benign and malignant variants, comprising various histological elements in pure or mixed form. The pathological classifications differed among geographic areas and countries, and even within countries depending of the system followed [1]. This significantly hampered the exchange of relevant information, both related to clinical handling of the respective patients as well as performing informative (translational) research studies. Mixing various subtypes of testicular GCTs will underestimate the potentially relevant observations, both in a clinical as well as a laboratory setting. Therefore, an alternative classification system is deemed necessitous and would be highly beneficial. This process started in 2005 by the introduction of a developmental biology–based alternative classification model, taking into account their potential
histological heterogeneity, predominantly fueled by knowledge of their (assumed) cell of origin [2,3]. The various GCT entities represent therefore defined, and well recognized from a developmental point of view, stages of germ cell maturation during physiological development, characterized by a set of (more or less) specific parameters. These include morphology, mRNA, microRNA, and protein profiles, as well as molecular genetic make-up (including epigenetics). Based on various independent confirmatory and multidisciplinary studies, this novel proposal was accepted unanimously at the last consensus meeting of the World Health Organization (WHO) held in 2015. It resulted in the current WHO classification (2016) [4,5], in which testicular GCTs (TGCTs) are subdivided into two main variants. These include the non-GCNIS-related and the GCNIS-related GCTs, also specifically summarized recently [3,6]. It must be kept in mind that the non-GCNIS-related GCTs encompass in fact two different types of TGCTs, being the pediatric teratomas/yolk sac tumors (Type I) and spermatocytic tumors (Type III) by virtue of having different cells of origin and pathogenesis. Therefore, they must not be mixed in the context of both clinical as well as laboratory studies.

The parameters related to cellular and histological composition, mRNA, microRNA and protein profiles, and genomic constitutions, are instrumental to recognize these various types, and as such crucial for diagnostic purposes. In addition, the parameters are instructive for both understanding their pathogenesis (i.e., cell of origin and initiating events), as well as progression related phenomena. Therefore, they will be highlighted hereunder, with the focus on those related to patients with disorders of sex development (DSD). Recognition of this overarching classification system resulted in identifying a well-defined set of biomarkers for primary (testicular) diagnosis as well as of metastatic and relapsed lesions.

2. Classification of GCNIS- and Non-GCNIS-Related Testicular GCTs

The types of testicular GCTs are divided into two main categories (Figure 1). The Type I and III testicular GCTs are together referred to as non-GCNIS-related GCTs. The Type II testicular GCTs are referred to as GCNIS-related GCTs. This is simply based on the recognition of the different cells of origin and related pathogenesis, in which the knowledge on the origin of the Type II tumors (i.e., GCNIS, see below), is the dominant player in the classification because of its well-recognized status. This distinction between the GCNIS-related and non-GCNIS-related testicular GCTs is of relevance because of their different clinical behavior, i.e., malignant versus (predominantly) benign. As such, they will be discussed separately. Of special notion is the fact that, so far, morphology, mRNA, microRNA, and protein profiles of (Type I and II) teratoma and yolk sac tumor elements are similar; therefore, noninformative to make a differential diagnosis. However, this is consistently the case regarding their molecular genetic make-up, being therefore of diagnostic value. In addition, various animal models have been reported to be informative for GCT, which will be summarized hereunder because of their potential impact in understanding the pathogenesis of this type of cancer (see also Figure 1).
Figure 1. Schematic representation of the various entities of testicular germ cell tumors (GCTs). The timeline is indicated on the left side and the proposed animal models on the right. The GCTs include the non-GCNIS (germ cell neoplasia in situ) related GCTs (left panel) and GCNIS-related GCTs (right panel). The non-GCNIS related GCTs are subcategorized into the prepubertal teratomas (TE) and yolk sac tumors (YST) as well as the spermatocytic tumors. These are also referred to as Type I and III, respectively. The GCNIS-related GCTs are histologically (and clinically) subdivided into the seminomas (SE) and the various elements of nonseminomatous GCTs, being embryonal carcinoma (EC), YST, choriocarcinoma, and TE. Note the overlapping histology between the prepubertal TE/YST and the TE and YST elements in the GCNIS-related nonseminomas. However, they have a separate (and independent) pathogenesis (see text for further details). The presumed cells of origin are indicated in green, reflecting a (partially and fully erased) primordial germ cell (Type I and II), to partially paternal imprinted spermatogonium/spermatocyte (Type III). The precursors are indicated when known (preinvasive), while specifically the benign and malignant behavior of the pediatric TE and YST is highlighted. In addition, the most prominent and recurrent molecular genetic changes are indicated, of putative interest to be used for molecular pathological approaches. These include total genomic anomalies, like polyploid/aneuploid, specific chromosomal imbalances like losses (-) and gains (+), as well as recurrent mutations (italics). In addition, the methylation status is indicated as well as the possible use of miR-371a-3p as a liquid biopsy molecular biomarker (underlined). All malignant histological elements, independent of age, are identified by this biomarker (except TE). The WNT pathway is specifically involved in the YST components, independent of age and also of pathogenesis.

3. Spontaneous and Laboratory-Generated GCT Animal Models

Final elucidation of the pathogenetic mechanisms of the various types of testicular GCTs, especially the earliest events involved, might be dependent on animal models (both spontaneous as well as laboratory-induced). For the non-GCNIS-related testicular GCTs (i.e., prepubertal teratomas/yolk sac tumors, Type I), various animal models have been proposed, both spontaneously occurring as well as generated by genetic modification, especially in mice [7]. This includes the prone strain of mice (129J)
that has been explained based on a dnd inactivating mutation [8]. Of interest is that a pleiotropy of genes disrupted in the embryonic germ cell lineage result in Type I-like teratomas (prepubertal type), including p53, pten, and ras [9,10], while formation of yolk sac tumor has been only reported rarely [11]. The likely spontaneous animal model for the other variant of non-GCNIS-related GCT (spermatocytic tumor; Type III testicular GCTs) is the dog [12], while also a genetically modified mouse model has been described, although being presented as mimicking seminoma (i.e., Type II) [13,14]. In addition, another laboratory generated mouse model has been reported for the pediatric (prepubertal type I) teratoma/yolk sac tumor. It is generated by combined forced expression of inactivated p53, myc, and oncogenic hras, resulting in tumors originating from embryonic like stem cells. In addition, this study also demonstrated that using the pluripotency factors, oct3/4, klf4, myc, and sex2 (also known as the Yamanaka factors, found to be diagnostically of relevance (as discussed in the section: immunohistochemistry GCNIS-related (Type II) GCTs), a pluripotent GCT was generated [15]. Most likely, the model being most similar to the human Type II GCTs is the mouse model elegantly generated using a germ cell specific activated kras and inactivation of pten [16]. The model generates malignant tumors composed of both embryonal carcinoma as well as teratoma, including metastatic capacity of the first. Moreover, the model supports the window of sensitivity to initiate these GCTs during prenatal development. It is tempting to speculate that this mimics the GCNIS-related GCTs, although confirmation is needed. In addition, two zebrafish models have been reported, seemingly informative for the pathogenesis of GCNIS-related GCTs, mainly seminoma (and possibly spermatocytic tumor) (also discussed below). These include the alkeb impaired model [17,18] as well as lrrc50 [19]. It remains so far to be proven what the actual relevance of these models is for the human pathologies observed, although they deserve further investigation.

4. Non-GCNIS-Related (Types I and III) Testicular GCTs: Cells of Origin

This category (to be discussed below in detail) includes pediatric (Type I) testicular GCTs, histologically composed of either teratomas and/or yolk sac tumor, predominantly diagnosed at early (pediatric) age. However, it is strongly recommended that the term “pediatric” GCTs is prevented as much as possible, because it will by definition result in a mixed population of these kind of tumors as well as GCNIS-related (Type II) GCTs, as recently demonstrated in a molecular study related to epigenetics (i.e., DNA methylation), clearly separating the two different entities of GCTs [20]. This mixture will dilute potentially relevant findings. The cell of origin of pediatric testicular teratoma/yolk sac tumor is still largely unidentified, although an early embryonic germ cell is most likely [21]. The other non-GCNIS related GCT is the so-called spermatocytic tumor (previously spermatocytic seminoma) (Type III testicular GCT). This is a well-defined entity only diagnosed in the post-pubertal testis, although sometimes misdiagnosed as seminoma. This variant originates from a more mature germ cell compared to the other GCTs, being either a spermatagonium or spermatocyte.

4.1. Prepubertal-Type Teratoma and/or Yolk Sac Tumors (Type I Testicular GCT)

As indicated, the prepubertal-type teratoma and/or yolk sac tumor (Type I GCTs) are predominantly diagnosed at an early age [22–26]. They can also occur later in life, although exceptionally [27,28]. Histologically these (Type I GCTs) can be composed of only two elements, either teratoma (representing potentially all germ layers, i.e., endo- ecto-, and mesoderm) and/or yolk sac tumor. The yolk sac tumor element progresses from the teratoma, representing the transition from benign to malignant. This is completely different from the pathogenesis of the GCNIS-related GCTs, in which the teratoma element(s) originate from an embryonal stem cell component, being embryonal carcinoma (to be discussed in detail later). Though morphologic features may be helpful, in a histologically pure teratoma, there are in principle two informative ways to investigate its malignant potential (i.e., behavior). This is based on demonstration of the presence (i.e., malignant) or absence (potential benign) of GCNIS (see below under Type II testicular GCTs) in the adjacent parenchyma. In the case of only atrophic seminiferous tubules, the absence of GCNIS must be interpreted with caution. In those cases, investigation of the
genomic composition (i.e., diploid versus aneuploid) is much more informative. In clinical practice, complete surgical removal (which is often the case in the testis) and presence of yolk sac tumor elements are the major clinical parameters predicting clinical behavior [29]. The general rule can be applied that if other histological elements are present apart from teratoma and yolk sac tumor, i.e., seminoma, embryonal carcinoma, or choriocarcinoma (in relation to their specific immunohistochemical profiles), the tumor must by definition be classified as a GCNIS derived (Type II), and as such be considered as malignant (see Figure 1 for decision making).

4.1.1. Risk Factors

Apart from familial predisposition, no other risk factors have been reported for this type of testicular GCTs.

4.1.2. Immunohistochemistry

Various immunohistochemical staining patterns have been reported to be informative for the identification of the various elements of teratoma, although none have a proven impact on prediction of malignant behavior, i.e., potential of yolk sac tumor formation. In fact, they are identical to their counterparts in GCNIS-related testicular GCTs and will be discussed below. In contrast, detection of Alpha Fetoprotein (AFP) and Glypican 3 is informative to detect presence of a yolk sac component, although not being absolute. Indeed, both false positive and negative findings are reported [5,30]. Considering the limitation of the immunohistochemical markers, evaluation of the molecular genetic composition is in principle more informative.

4.1.3. Molecular Genetic Constitution

The prepubertal teratomas, independent of the level of maturity as well as histological composition (ecto-, endo-, and mesoderm) are diploid (46,XY) without recurrent somatic mutations [31–33]. No mutations have been identified in the assumed candidate gene DND, based on mouse studies so far [34]. In contrast, the pediatric yolk sac tumors are always aneuploid, having defined chromosomal gains and losses. These relate to chromosome 1 (gain), 6q (loss), and part of 12p (gain, in particularly 12p13) [33,35]. The genes proposed to be involved are STELLA, NANOG, and GDF3. This is a relevant observation and must be kept in mind by interpreting (fluorescent) in situ hybridization ((F)ISH) data in the context of distinguishing a non-GCNIS- and GCNIS-related yolk sac tumor [36,37]. In fact, the method to be applied is a significant relevance, based on selected probes using FISH, or more broad copy number variations (CNV). In addition, loss of 6q is also found (specifically) in GCNIS-related yolk sac tumors, suggesting that it is related to formation of this specific differentiation lineage [38,39].

Apart from FISH, other molecular assays can be applied to detect CNV, including targeted PCR bases assays, single nucleotide polymorphism (SNP)- or DNA methylation-based arrays GCTs (450K and EPIC, for example) [20,39–41]. In addition to tumor specific molecular genetic changes, it has been identified that a number of SNPs are related to development of pediatric (including testicular) GCTs (of various anatomical localizations). These variants are present in the constitution DNA of the patient, and as such have to considered as susceptibility alleles, likely in interaction with environmental factors [42,43]. They are likely related, amongst others, to the targets BAK1 and SPRY4, interestingly involved in regulation of apoptosis of an embryonic germ cell. It remains to be determined what the exact impact of this observation is for the pediatric testicular teratomas/yolk sac tumors specifically. No genome-wide studies on the presence of somatic mutations have been reported so far. The selected studies all indicate that mutations are in fact rare, fitting with an embryonic germ cell lineage origin, allowing little-to-no mutations to be transferred to the next generation [44–46]. Progression of the teratoma elements to so-called somatic type malignancy might occur, showing the same genetic anomalies [47,48]. WNT signaling has been specifically identified in yolk sac tumor, including GCNIS-related subtype [49,50]. This might be related to the induction of cisplatin resistance [51,52].
4.2. Spermatocytic Tumors (Type III Testicular GCT)

The spermatocytic (Type III) GCTs were historically diagnosed as spermatocytic seminoma, based on the assumed similarities to seminoma [53], now simply renamed as spermatocytic tumor in the WHO 2016 classification system [5]. They are predominantly found in elderly men and their pathogenesis has been elucidated in large detail [53–68]. The cell of origin is either a spermatogonium or spermatocyte, in line with their cellular composition, RNA, and protein profile. They classically are composed of three cell types, being small, intermediate, and large. The precursor is known as intratubular spermatocytic tumor, filling up the seminiferous tubules, pushing the sertoli cells outwards, in contrast to the situation found in case of GCNIS. Clinically, spermatocytic tumors are indolent, although bilateral occurrence and very rare progression to sarcoma must be kept in mind [69,70]. The mechanistic explanation for these observations are lacking so far, although assuming spermatocytic tumors being only a hyperproliferative lesion, of which its molecular basis is possibly more systemic than (tumor) cell specific is tempting. In addition, intermediate characteristics between the Type II and III GCTs, as proposed in the most update classification [3], is a possibility as well. The answers to these questions will be obtained through detailed investigations of the cellular as well as molecular makeup of these unique cases in the context of the most recent classification.

4.2.1. Risk Factors

So far, no risk factors have been reported for spermatocytic tumors.

4.2.2. Immunohistochemistry

Various proteins have been identified to be informative for the diagnosis of spermatocytic tumors, especially in a comparative set up with seminoma (see below). These include XPA, CYP1, SSX2-4, as well as DMRT1 [71], CHK2, P53, p16INK4d and MAGE-4A [72], OCT2 and SAGE1 [73], NUT, and GAGE7 and NY-ESO-12 [66], being so-called testis-cancer-antigens. Of specific interest is DMRT1 [74]. This gene is mapped to chromosome 9, of specific relevance for spermatocytic tumors because of its consistent gain (discussed in the next paragraph). Most recently, it has been suggested that two variants of spermatocytic tumors exist, defined by specific protein profiles, and related to absence and presence of defined somatic mutations [63,65,68].

4.2.3. Molecular Genetic Constitution

The spermatocytic tumors have a unique chromosomal constitution [53,57,61,63,65,68,75]. All investigated cases so far show additional copies (i.e., gain) of chromosome 9, being of diagnostic relevance. In fact, no changes have been reported in pediatric teratomas/yolk sac tumors for this chromosome, while loss is predominantly found in the GCNIS-related GCTs [39]. The candidate gene might be DMRT1, located in the short arm of chromosome 9, found to be amplified in a unique case, while expression is found in all [61]. Overall, spermatocytic tumors hardly show chromosomal breakage, resulting in sub-chromosomal gain and losses, although apart from gain of chromosome 9, loss of chromosome 7 was predominantly found [65,68]. The genes suggested to be involved are, apart from DMRT1, also SOHLH1, DNMT3b, CTCFL/BORIS, and STRA7 (on chromosome 7). In addition, they hardly show somatic mutations, with the exception of two, being HRAS and FGFR3. Of specific notion is that these mutations can be found in sperm of elderly males, related to development of defined syndrome in the offspring referred to as selfish spermatogonial selection [65,76–78]. In conclusion, diagnostic distinction between spermatocytic tumor and seminoma (see below) can be accomplished using immunohistochemistry (preferentially using OCT3/4 and DMRT1) as well as molecularly (using FISH or CNV-based differences, focusing predominantly on chromosome 9 and 12p).
4.3. GCNIS-Related Testicular GCTs: Type II—Histological Diversity and Cell of Origin

All GCNIS-related testicular GCTs (also referred to as Type II GCTs) originate from a single precursor lesion, known as germ cell neoplasia in situ (GCNIS) according to the latest WHO classification [5], previously referred to as carcinoma in situ (CIS) [79], intratubular germ cell neoplasia, unclassified (IGCNU), or testicular intratubular neoplasia (TIN) [80] (Figure 2). The GCNIS cells represent an embryonic germ cell (i.e., primordial germ cells/gonocytes), characterized by several characteristics. The cells are in principle totipotent (omnipotent), and able to generate all differentiation lineages as can be found during embryonal development, both somatic (teratoma, including all three germ layers) as well as extra embryonic (yolk sac tumor and choriocarcinoma). Moreover, the germ cell lineage itself can be re-initiated in non-seminomas [81], representing the circle of life in full perspective, i.e., demonstrating its omnipotent character. Clinically, GCNIS-related testicular GCTs are categorized into seminomas and non-seminomas. While the former shows a rather homogeneous composition, representing in fact invasive GCNIS-like cells, the latter can contain all histological elements as found during physiological intra-uterine development, originating from the stem cell component embryonal carcinoma (representing embryonic stem cells). About 50% of GCNIS progress to seminoma and the other to non-seminomas.

![Figure 2. Representative examples of germ cell neoplasia in situ (GCNIS) (top two rows) (patient 30 years of age with a pure seminoma and GCNIS) stained using Hematoxylin & Eosin (H&E) (A) and immunohistochemistry for OCT3/4 (B), TSPY(C), KITLG (D), SOX9 (Sertoli cell marker) (E), as well as direct alkaline phosphatase (dAP) (F). In addition, the lower row shows a prepubertal testis with delayed maturation (H&E (G) and OCT3/4 positive (H)), as well as the “false” positive staining for KIT in normal spermatogonia (being OCT3/4 negative) (I). Multiplication 200×, except for G,H 100×.](image)

Although GCNIS is the proven testicular precursor of all Type II GCTs, the potential origin from gonadoblastoma (GB), albeit rare, must be considered, especially in the context of dysgenetic gonads [82–87]. This lesion is also composed of embryonic germ cells (like GCNIS, being OCT3/4
positive, see below), but now in the context of granulosa cells (being FOXL2 positive) instead of sertoli cells (SOX9 positive) (see Figure 3) [85,88]. It must be recognized that SOX9 can also be positive in rete testis, epididymis, and ductus deferens. GB must be clearly distinguished from intratubular seminoma based on the potential risk of a contralateral GCNIS-related GCT in these patients, related to one of the major risk factors for Type II GCTs, being disorders of sex development (DSD). Therefore, if a GB is diagnosed it must activate the clinical protocol for the patient assuming an underlying DSD [89]. This includes standardized pathological examination of the contralateral gonadal tissue (either biopsy or orchiectomy) [90]. Except in case of a retroperitoneal localization of a (assumed) GCT, the sole localization in the mediastinum is not indicative to exclude the presence of a testicular origin, i.e., demonstration of the presence of GCNIS, although they will contain gain of 12p if they are of the GCNIS-related like variant (Type II) [91,92].

Figure 3. Representative examples of gonadoblastoma (GB) stained using Hematoxylin & Eosin (H&E) (A) and immunohistochemistry for OCT3/4 (B), TSPY (C), KITLG (D), FOXL2 (granulosa cell marker) (E), as well as direct alkaline phosphatase (dAP) (F). Multiplication 200×.

4.3.1. Risk Factors

The GCNIS-related (testicular) GCTs are known for the presence of a number of well-recognized risk factors, including cryptorchidism, in-/subfertility, familial predisposition, birth weight, and possibly hypospadias [6,87,93]. In addition, the aforementioned DSD has been found to be a major risk factor for this type of GCT [82,94–101]. Of additional relevance is the fact that these GCTs are predominantly found in young males between 20 and 45 years of age of a European descent, likely related to defined SNPs (discussed in detail below).
4.3.2. Immunohistochemistry

GCNIS (as well as GB) cells show a consistent demethylated genome, detectable by immunohistochemistry [102–104], as well as a defined expression profile, both related to mRNA, microRNA, as well as proteins [21,105,106]. The profiles indeed mimic primordial germ cells/gonocytes, amongst others highlighted by the expression of OCT3/4, also known as OCT3 or OCT4 or POU5F1 [107–109]. The use of Bouin of Stieve’s fixatives might result in suboptimal and even false negative findings. In addition, these cells are also positive for PLAP (placental-like alkaline phosphatase), and cKIT, although the latter can result in overdiagnosis because of low expression in normal spermatogonia [110] (see Figure 2). In addition, they have a high glycogen content, to be detected using PAS. Moreover, the PLAP expression can be visualized using the direct enzymatic staining method [111]. Representative examples of the in the 2016 WHO-included diagnostic markers are given in Figures 2 and 3.

Possible overdiagnosis at early age, in particular in the first year of postnatal life, for example in case of cryptorchidism repair surgery or DSD, is of specific relevance, for which the markers KITLG (stem cell factor) as well as TSPY (Testis Specific Protein on the Y chromosome) is of interest to be applied [90,112]. The various histological elements of invasive GCTs can be diagnosed using a number of informative proteins. The most relevant and informative are the (nuclear) transcription factors SOX17 and SOX2 to identify, in combination with OCT3/4, seminoma as well as embryonal carcinoma [113]. The yolk sac tumor and choriocarcinoma elements can be detected using AFP and hCG (human ChorioGonadotropin), respectively, although SALL4 and Glypican 4 are informative as well. Loss of PTEN has been reported to be related to the transition from GCNIS to an invasive GCT [114].

4.3.3. Molecular Genetic Constitution

The finding on KITLG (see above) as one of the earliest changes in the transition from a primordial germ cell/gonocyte to pre-GCNIS [90] is, apart from diagnostic value, also relevant in the context of pathogenesis. It interestingly links the identification of specific single nucleotide polymorphisms (SNPs) associations to development of GCNIS-related testicular GCTs. Genome wide association studies (GWAS) demonstrate a reported link between the susceptibility SNPs and the KIT pathway related to primordial germ cell migration, survival, and proliferation [115–120]. Moreover, the other identified pathways are centrosome cycle, in line with other independently generated datasets [121]. The additional link to sex determination is obvious, based on DSD being one of the main risk factors, as well as GCNIS and GB being precursors. Moreover, the reported link to apoptosis (via CHEK2, GSPT1, and BRCA1) and DNA damage repair (RAD51 and BRCA1, amongst others) is of particular interest based on the mutational signature reported (see below). In addition, relevant variants, not identified by GWAS studies, have been identified based on a previously reported (lrrc50) zebrafish model, being related to ciliary function, found to be significant in GCNIS-related testicular GCTs, of which so far it is not clear whether it is related directly at the germ cell itself, or is related to the microenvironment [19,122]. In fact, to date it is not clear whether all variants act similarly during the pathogenesis of the GCNIS-related GCTs, or if some act early (for example during formation of GCNIS) and others late (for example progression to invasiveness). Such a heterogeneity might be expected based on targeted analyses of variants in patients with DSD [123].

The vast majority of histological elements of GCNIS-related testicular GCTs are characterized by extra copies (overrepresentation) of the short arm of chromosome 12, mostly as isochromosome 12p (i12p) [124–128]. This CNV is absent in GCNIS, and it is related to invasive growth [129]. This has been independently confirmed most recently based on purified GCNIS subpopulations [130]. Apart from gain of 12p, a number of tumors, predominantly seminomas, show high level amplification on specific subregions of 12, including KRAS [127,131–134]. While still a number of GCNIS-related GCTs are reported without gain of 12p, predominantly seminomas [39,135], and are suggested to have a (slightly) different pathogenesis (with preferential cKIT mutations), which is of relevance to
keep in mind in the context of molecular pathology. In addition, it might be of specific relevance to investigate these cases to identify the important genes on 12p in more detail. It supported the model that polyploidization is one of the first steps in the formation of GCNIS. The study in addition provided strong indications that most of the GCNIS cells (without gain of 12p or \(cKIT\) mutations) will not progress to an invasive GCT. In that context it is relevant to state that so far it is not proven that all GCNIS will progress to full blown cancer, of relevance for screening purposes. Gain of 12p can be detected using various approaches, including FISH, SNP array, as well as the methylation array (450K or EPIC) [37,39,40,124,127,132,134,136]. For these later approaches, the presence of sufficient amount of tumor cells is a logical prerequisite for proper interpretation.

Regarding mutational status, a number of targeted and high throughput studies have been reported [117,137–139]. The most extensive multidisciplinary study on GCNIS-related testicular GCT was recently reported by Shen et al. [135]. Overall, the results are in the same direction. They, independent of histological composition, have a very low frequency of somatic mutations of about ~0.1–0.5 per Mb, with only a few exceptions, being in the same range as pediatric (non-GCNIS) cancer as well as spermatocytic tumors. It is likely that this is related to the evolutionary mechanism preventing transmission of (harmful) genetic changes to the next generation. Based on CNV and mutational status, two variants of seminomas do seem to exist, one with and one without \(cKIT\) mutations, whereby the wild type variants do show a higher level of genome methylation. In addition, there is likely a less prominent presence of gain of 12p in the \(cKIT\) mutated seminomas. The data supporting this hypothesis are obtained both from intracranial cases [140] as well as of the post pubertal testis [135]. The results indicate that, although recurrent, these two mechanisms are seemingly partly overlapping. A dedicated study on this specific finding would be of significance, because it might reveal the possible responsible genes on 12p related to progression from GCNIS to invasive growth [129]. In this context, it is of relevance to indicate that the largest DNA methylation series of testicular Type II GCTs excludes those lacking gain of 12p [39]. Specific reanalysis of these cases might therefore be of specific interest.

Apart from \(cKIT\), mutations, or amplification [141,142], only \(KRAS\), \(NRAS\), and to (even) a lower extent \(PI3CA\), seem to be affected by mutations. In the context of the \(cKIT-KITLG\) loop, either autocrine or paracrine, the loss of \(KITLG\) in non-seminomas is of interest [143]. CNV seems to be more profound, including of course \(KRAS\) (being on 12p). In addition, amplification of \(MDM2\) was also found, being in accordance to earlier findings, showing that the P53/MDM2 axis is involved in therapy resistance [144,145]. In addition, other possible targets are identified as well, being \(RAC1\) and \(FAT1\), possibly used for targeted therapy in some cases. [146,147]. In this context, a more targeted therapy can be applied [146]. In addition, microsatellite instability has been reported to be involved with cisplatin resistance [148], although not identified in the largest series investigated, possibly due to bias to mainly treatment sensitive cases [135]. The only study that included the matched GCNIS to the invasive non-seminoma mutations status demonstrated that none of the mutations are identified in the precursor lesion GCNIS, while being already aneuploid [130]. This indicates that the mutational load, although overall low, is related to progression and is also found to be heterogenous within the primary tumors, possibly even absent, while most likely related to therapy resistance at metastatic sites.

The results obtained so far support the model that GCNIS-related testicular GCTs are in fact developmental cancers, in which a disturbed microenvironment, possibly initiated by the supportive cells, resulting in an inappropriate niche for the gonadal embryonic germ cells for proper maturation is one the major risk factors for the development of this cancer [2,6,21,59,149–154]. This must be kept in mind related to optimal diagnosis. In other words, no highly informative molecular biomarkers are identified except CNV (i.p. gain of 12p), as well as mutations in a limited number of genes (\(K\)-and \(NRAS\), as well as \(PI3CA\)). However, more developmentally related parameters could be a target of interest, even as liquid biopsy molecular biomarkers. These include overall methylation status, for example demethylation of \(DPP3A\) [39], hypermethylation of \(RASSF1A\) [155], or alternatively X inactivation and related hypomethylation of the related \(XIST\) promotor, uniquely found in GCNIS related (Type II) testicular GCTs in males [156,157]. However, one of the major candidates, relatively close to be
implemented in clinical practice for malignant GCTs, both pediatric yolk sac tumors and GCNIS-related GCTs (except teratoma) is detection of embryonic microRNAs, in particular miR-371a-3p.

5. Application of miR-371a-3p as Molecular Biomarker for Malignant GCTs in Liquid Biopsies

The field of analyses of the potential use of miR-371a-3p as molecular biomarker for GCTs started by the publication in 2006 [158]. That study demonstrated that the members of the miR-371-3 can function as an alternative mechanism for inactivation of the P53 pathway without inactivation mutations due to LATS2 interaction. This resulted in absence of cellular senescence, now reported to be the case for all three members [159]. Another putative target of interest in RAD51 is related to DNA damage response (see above). Expression of miR-371a-3p was found, both using a high throughput as well as a targeted approach, to be highly informative in identifying the malignant component of GCTs [160–162]. Subsequently, it was demonstrated that it can be detected in serum, plasma, as well as cerebrospinal fluids of patients with a malignant GCT (either GCNIS-related or non-related, Type I or II) as well as in appropriate mouse xenograft models [163–175]. The only known origin of physiological expression is in spermatogonia [176]. The results so far demonstrate that miR-371a-3p is significantly more informative compared to the golden standard AFP and hCG, because it is expressed in all malignant elements, except teratoma. An alternative miR, being miR-375, has been suggested to be informative for teratoma as well, although not proven so far [135].

6. Conclusions

A summary regarding the current knowledge on the classification and (potential) biomarkers of GCTs is represented in Figure 1. These specifically relate to the various types of testicular GCTs, being both variants in the non-GCNIS-related and GCNIS-related tumors. Especially, CNV are informative to distinguish the types besides histological composition. Specifically, gain of the short arm of chromosome 12 for the invasive GCNIS-related components, and gain of chromosome 9 for the spermatocytic tumors. In addition, aneuploid and loss of 6q in the prepubertal yolk sac tumor, in contrast to the prepubertal teratoma, while all GCNIS-related teratoma are aneuploid and mostly contain gain of 12p. The methylation as well as mutational profiles are less informative, based on the possible overlap as well as (overall) low frequencies, respectively. The GCNIS-related, i.e., Type II GCTs, by definition malignant, are relevant in the context of patients with DSD. Identification of the precursor lesion, based on a defined set of histology-based biomarkers, including OCT3/4, TSPY, and KITLG, is crucial for proper risk stratification. Of particular interest is the miR-371a-3p, found to be highly informative for all malignant GCT components, both in pediatric and (young) adult patients, suitable to be used as liquid-biopsy based molecular biomarker. It is expected that it will change clinical handling of patients with GCTs of the testis as well as other anatomical localizations (extra-cranial and cranial) drastically within the coming years. Based on the data available so far, it will outperform the currently used golden standards AFP and hCG. However, liquid biopsy-based informative biomarkers for the precursor lesions, i.e., GCNIS as well as GB, relevant for screening of DSD patients at risk are still lacking.

Author Contributions: L.H.J.L. wrote the first versions, approved and adjusted by C.-S.K. and M.T.I.

Funding: L.H.J.L. is funded by the Princes Máxima Center for Pediatric Oncology through financial support by KiKa (Stichting Kinderen Kankervrij).

Acknowledgments: The authors would like to thanks all patients, clinicians, and scientists for their contributions to the work presented.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Abbreviations

- AFP: Alpha Fetoprotein
- CIS: Carcinoma In Situ
- CNV: copy number variations
- DSD: Disorders of Sex Development
- EC: embryonal carcinoma
- (F)ISH: (Fluorescent) In Situ Hybridization
- GB: Gonadoblastoma
- GBY: Gonadoblastoma on the Y chromosome
- GCNIS: Germ cell neoplasia in situ
- GCTs: Germ Cell Tumors
- GGCC: gonadal germ cell cancer
- GWAS: Genome wide association studies
- (h)CG: human ChorioGonadotropin
- IGCNU: Intratubular Germ Cell Neoplasia, Unclassified
- PLAP: Placental like alkaline phosphatase
- SE: seminoma
- SNP: Single Nucleotide Polymorphism
- TE: teratoma
- TSPY: Testis specific protein on the Y chromosome
- TIN: Testicular Intratubular Neoplasia
- YST: yolk sac tumor
- WHO: World Health Organization

References

1. Rosai, J.; Ackerman, L.V. Surgical Pathology, 9th ed.; Rosai & Ackerman’s Surgical Pathology: Edinburgh, UK; New York, NY, USA, 2004; p. 3080.
2. Oosterhuis, J.W.; Looijenga, L.H. Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer 2005, 5, 210–222. [CrossRef]
3. Oosterhuis, J.W.; Looijenga, L.H.J. Germ cell tumors from a developmental perspective. Nat. Rev. Cancer 2019, 19, 522–537. [CrossRef] [PubMed]
4. Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 who classification of tumours of the urinary system and male genital organs-part a: Renal, penile, and testicular tumours. Eur. Urol. 2016, 70, 93–105. [CrossRef] [PubMed]
5. Moch, H.; Humphrey, P.A.; Ulbright, T.M.; Reuter, V.E. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed.; IARC: Lyon, France, 2016.
6. Cheng, L.; Albers, P.; Berney, D.M.; Feldman, D.R.; Daugaard, G.; Gilligan, T.; Looijenga, L.H.J. Testicular cancer. Nat. Rev. Dis. Primers 2018, 4, 29. [CrossRef] [PubMed]
7. Looijenga, L.H. Testicular germ cell tumors. Pediatr. Endocrinol. Rev. 2014, 11 (Suppl. 2), 251–262.
8. Younggren, K.K.; Covenev, D.; Peng, X.; Bhattacharya, C.; Schmidt, L.S.; Nickerson, M.L.; Lamb, B.T.; Deng, J.M.; Behringer, R.R.; Capel, B.; et al. The ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature 2005, 435, 360–364. [CrossRef] [PubMed]
9. Salz, H.K.; Dawson, E.P.; Heaney, J.D. Germ cell tumors: Insights from the drosophila ovary and the mouse testis. Mol. Reprod. Dev. 2017, 84, 200–211. [CrossRef] [PubMed]
10. Zechel, J.L.; MacLennan, G.T.; Heaney, J.D.; Nadeau, J.H. Spontaneous metastasis in mouse models of testicular germ-cell tumours. Int. J. Androl. 2011, 34, e278–e287. [CrossRef] [PubMed]
11. Van Berlo, R.J.; Oosterhuis, J.W.; Schrijnemakers, E.; Schoots, C.J.; de Jong, B.; Damjanov, I. Yolk-sac carcinoma develops spontaneously as a late occurrence in slow-growing teratoid tumors produced from transplanted 7-day mouse embryos. Int. J. Cancer 1990, 45, 153–155. [CrossRef]
12. Looijenga, L.H.; Olie, R.A.; van der Gaag, I.; van Sluijs, F.J.; Matoska, J.; Ploem-Zaaijer, J.; Kneip, C.; Oosterhuis, J.W. Seminomas of the canine testis. Counterpart of spermatocytic seminoma of men? Lab. Investig. 1994, 71, 490–496.
13. Meng, X.; de Rooij, D.G.; Westerdahl, K.; Saarma, M.; Sariola, H. Promotion of seminomatous tumors by targeted overexpression of glial cell line-derived neurotrophic factor in mouse testis. *Cancer Res.* 2001, 61, 3267–3271. [PubMed]

14. Sariola, H.; Meng, X. Gdnf-induced seminomatous tumours in mouse—An experimental model for human seminomas? *APMS* 2003, 111, 192–196, discussion 196. [CrossRef] [PubMed]

15. Morimoto, H.; Lee, J.; Tanaka, T.; Ishii, K.; Toyokuni, S.; Kanatsu-Shinohara, M.; Shinohara, T. In vitro transformation of mouse testis cells by oncogene transfection. *Biol. Reprod.* 2012, 86, 1–11. [CrossRef] [PubMed]

16. Pierpont, T.M.; Lyndaker, A.M.; Anderson, C.M.; Jin, Q.; Moore, E.S.; Roden, J.L.; Braxton, A.; Bagepalli, L.; Kataria, N.; Hu, H.Z.; et al. Chemotherapy-induced depletion of oct4-positive cancer stem cells in a mouse model of malignant testicular cancer. *Cell Rep.* 2017, 21, 1896–1909. [CrossRef] [PubMed]

17. Neumann, J.C.; Chandler, G.L.; Damoulis, V.A.; Fustino, N.J.; Lillard, K.; Looijenga, L.; Margraf, L.; Rakheja, D.; Amatruda, J.F. Mutation in the type ib bone morphogenetic protein receptor alk6b impairs germ-cell differentiation and causes germ-cell tumors in zebrafish. *Proc. Natl. Acad. Sci. USA* 2011, 108, 13153–13158. [CrossRef] [PubMed]

18. Neumann, J.C.; Lillard, K.; Damoulis, V.; Amatruda, J.F. Zebrafish models of germ cell tumor. *Methods Cell Biol.* 2011, 105, 3–24. [PubMed]

19. Basten, S.G.; Davis, E.E.; Gillis, A.J.; van Rooijen, E.; Logister, I.; Heath, Z.G.; Jonges, T.N.; Katsanis, N.; et al. Mutations in Irlrc50 predispose zebrafish and humans to seminomas. *PLoS Genet.* 2013, 9, e1003384. [CrossRef]

20. Amatruda, J.F.; Ross, J.A.; Christensen, B.; Fustino, N.J.; Chen, K.S.; Hooten, A.J.; Nelson, H.; Kuriger, J.K.; Rakheja, D.; Frazier, A.L.; et al. DNA methylation analysis reveals distinct methylation signatures in pediatric germ cell tumors. *BMC Cancer* 2013, 13, 313. [CrossRef]

21. Oosterhuis, J.; Looijenga, L.H.J. Germ cell tumors: Pathology and genetics. In *Encyclopedia of Cancer*, 3rd ed.; Boersma, P., Hainaut, P., Eds.; Elsevier Inc.: Amsterdam, The Netherlands, 2019; Volume 2, pp. 121–153.

22. Schneider, D.T.; Calaminus, G.; Koch, S.; Teske, C.; Schmidt, P.; Haas, R.J.; Harms, D.; Gobel, U. Epidemiologic analysis of 1,442 children and adolescents registered in the german germ cell tumor protocols. *Pediatr. Blood Cancer* 2004, 42, 169–175. [CrossRef]

23. Stang, A.; Trabert, B.; Wentzensen, N.; Cook, M.B.; Rusner, C.; Oosterhuis, J.W.; McGlynn, K.A. Gonadal and extragonadal germ cell tumours in the united states, 1973–2007. *Int. J. Androl.* 2012, 35, 616–625. [CrossRef]

24. Poynter, J.N.; Amatruda, J.F.; Ross, J.A. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the united states, 1975 to 2006. *Cancer* 2010, 116, 4882–4891. [CrossRef] [PubMed]

25. Hubbard, A.K.; Spector, L.G.; Fortuna, G.; Marcotte, E.L.; Poynter, J.N. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988–2012. *JNCI Cancer Spectr.* 2019, 3, pkz007. [CrossRef] [PubMed]

26. Kuksler, K.A.; Poynter, J.N. International testicular cancer incidence rates in children, adolescents and young adults. *Cancer Epidemiol.* 2018, 56, 106–111. [CrossRef] [PubMed]

27. Oosterhuis, J.W.; Stoop, J.A.; Rijlaarsdam, M.A.; Biermann, K.; Smit, V.T.; Hersmus, R.; Looijenga, L.H. Pediatric germ cell tumors presenting beyond childhood? *Andrology* 2015, 3, 70–77. [CrossRef] [PubMed]

28. Zhang, C.; Berney, D.M.; Cheng, L.; Ulbright, T.M. Evidence supporting the existence of benign teratomas of the postpubertal testis: A clinical, histopathologic, and molecular genetic analysis of 25 cases. *Am. J. Surg Pathol.* 2013, 37, 827–835. [CrossRef] [PubMed]

29. Harms, D.; Zahn, S.; Gobel, U.; Schneider, D.T. Pathology and molecular biology of teratomas in childhood and adolescence. *Klin. Padiatr.* 2006, 218, 296–302. [CrossRef] [PubMed]

30. Ulbright, T.M.; Tickoo, S.K.; Berney, D.M.; Srigley, J.R.; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in testicular tumors: Report from the international society of urological pathology consensus conference. *Am. J. Surg Pathol.* 2014, 38, e50–e59. [PubMed]

31. Oosterhuis, J.W.; Looijenga, L.H.; van Echten, J.; de Jong, B. Chromosomal constitution and developmental potential of human germ cell tumors and teratomas. *Cancer Genet. Cytogenet.* 1997, 95, 96–102. [CrossRef]

32. Cornejo, K.M.; Cheng, L.; Church, A.; Wang, M.; Jiang, Z. Chromosome 12p abnormalities and imp3 expression in prepubertal pure testicular teratomas. *Hum. Pathol* 2016, 49, 54–60. [CrossRef] [PubMed]
33. Mostert, M.; Rosenberg, C.; Stoop, H.; Schuyer, M.; Timmer, A.; Oosterhuis, W.; Looijenga, L. Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab. Invest. 2000, 80, 1055–1064. [CrossRef] [PubMed]

34. Linger, R.; Dudakia, D.; Huddart, R.; Tucker, K.; Friedlander, M.; Phillips, K.A.; Hogg, D.; Jewett, M.A.; Lobynska, R.; Daugaard, G.; et al. Analysis of the dnd1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer 2008, 47, 247–252. [CrossRef] [PubMed]

35. Perlman, E.J.; Hu, J.; Ho, D.; Cushing, B.; Lauer, S.; Castleberry, R.P. Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization. J. Pediatr. Hematol Oncol. 2000, 22, 100–105. [CrossRef] [PubMed]

36. Perlman, E.J.; Valentine, M.B.; Griffin, C.A.; Look, A.T. Deletion of 1p36 in childhood endodermal sinus tumors by two-color fluorescence in situ hybridization: A pediatric oncology group study. Genes Chromosomes Cancer 1996, 16, 15–20. [CrossRef]

37. Mostert, M.M.; van de Pol, M.; van Echten, J.; Olde Weghuis, D.; Geurts van Kessel, A.; Oosterhuis, J.W.; Looijenga, L.H. Fluorescence in situ hybridization-based approaches for detection of 12p overrepresentation, in particular i(12p), in cell lines of human testicular germ cell tumors of adults. Cancer Genet. Cytogenet. 1996, 87, 95–102. [CrossRef]

38. Looijenga, L.H.; Rosenberg, C.; van Gurp, R.J.; Geelen, E.; van Echten-Arends, J.; de Jong, B.; Mostert, M.; Wolter Oosterhuis, J. Comparative genomic hybridization of microdissected samples from different stages in the development of a seminoma and a non-seminoma. J. Pathol. 2000, 191, 187–192. [CrossRef]

39. Killian, J.K.; Dorssers, L.C.; Trabert, B.; Gillis, A.J.; Cook, M.B.; Wang, Y.; Waterfall, J.J.; Stevenson, H.; Smith, W.I., Jr.; Noyes, N. Imprints and DPPA3 are bypassed during pluripotency-and differentiation-coupled methylation reprogramming in testicular germ cell tumors. Genome Res. 2016, 26, 1490–1504. [CrossRef] [PubMed]

40. Malek, N.P.; Casper, J.; Looijenga, L.H.; Strohmeyer, T.; Schmoll, H.J.; Nordheim, A.; Janknecht, R. Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. Eur J. Cancer 1997, 33, 1488–1494. [CrossRef]

41. LeBron, C.; Pal, P.; Brait, M.; Dasgupta, S.; Guerrero-Preston, R.; Looijenga, L.H.; Kowalski, J.; Netto, G.; Hoque, M.O. Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. Genomics 2011, 97, 341–349. [CrossRef]

42. Poynter, J.N.; Hooten, A.J.; Frazier, A.L.; Ross, J.A. Associations between variants in kitlg, spry4, bak1, and dmrt1 and pediatric germ cell tumors. Genes Chromosomes Cancer 2012, 51, 266–271. [CrossRef]

43. Marcotte, E.L.; Pankratz, N.; Amatruda, J.F.; Frazier, A.L.; Krailo, M.; Davies, S.; Starr, J.R.; Lau, C.C.; Roesler, M.; Langer, E.; et al. Variants in bak1, spry4, and gab2 are associated with pediatric germ cell tumors: A report from the children’s oncology group. Genes Chromosomes Cancer 2017, 56, 548–558. [CrossRef]

44. Sakumi, K. Germine mutation: De novo mutation in reproductive lineage cells. Genes Genet. Syst. 2019, 94, 3–12. [CrossRef]
51. Pfankuchen, D.B.; Baltes, F.; Batool, T.; Li, J.P.; Schlesinger, M.; Bendas, G. Heparin antagonizes cisplatin resistance of a2780 ovarian cancer cells by affecting the wnt signaling pathway. *Oncotarget* 2017, 8, 67553–67566. [CrossRef] [PubMed]

52. Mueller, T.; Pfankuchen, D.B.; Wantoch von Rekowski, K.; Schlesinger, M.; Reipsch, F.; Bendas, G. The impact of the low molecular weight heparin tinzaparin on the sensitization of cisplatin-resistant ovarian cancers-preclinical in vivo evaluation in xenograft tumor models. *Molecules* 2017, 22, 728. [CrossRef] [PubMed]

53. Looijenga, L.H.; Stoop, H.; Hersmus, R.; Gillis, A.J.; Wolter Oosterhuis, J. Genomic and expression profiling of human spermatocytic seminomas: Pathogenetic implications. *Int. J. Androl.* 2007, 30, 328–335, discussion 335–326. [CrossRef]

54. Scully, R.E. Spermatocytic seminoma of the testis. A report of 3 cases and review of the literature. *Cancer* 1961, 14, 788–794. [CrossRef]

55. Barr, W.B., Jr.; Silberg, S. A case report and review of the literature on spermatocytic seminoma of the testis. *J. Urol.* 1963, 89, 464–466. [CrossRef]

56. Rosai, J.; Silber, I.; Khodadoust, K. Spermatocytic seminoma. I. Clinicopathologic study of six cases and review of the literature. *Cancer* 1969, 24, 92–102. [CrossRef]

57. Oosterhuis, J.W.; Castedo, S.M.; de Jong, B.; Cornelisse, C.J.; Dam, A.; Sleijfer, D.T.; Schraffordt Koops, H. Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance. *Lab. Invest.* 1989, 60, 14–21. [PubMed]

58. Pendlebury, S.; Horwich, A.; Dearnaley, D.P.; Nicholls, J.; Fisher, C. Spermatocytic seminoma: A clinicopathological review of ten patients. *Clin. Oncol.* 1996, 8, 316–318. [CrossRef]

59. Looijenga, L.H.; Oosterhuis, J.W. Pathogenesis of testicular germ cell tumours. *Rev. Reprod.* 1999, 4, 90–100. [CrossRef] [PubMed]

60. Chung, P.W.; Bayley, A.J.; Sweet, J.; Jewett, M.A.; Tew-George, B.; Gospodarowicz, M.K.; Warde, P.R. Spermatocytic seminoma: A review. *Eur. Urol.* 2004, 45, 495–498. [CrossRef]

61. Looijenga, L.H.; Hersmus, R.; Gillis, A.J.; Pfundt, R.; Stoop, H.J.; van Gurp, R.J.; Veltman, J.; van Drunen, E.; van Kessel, A.G.; et al. Genomic and expression profiling of human spermatocytic seminomas: Primary spermatocyte as tumorigenic precursor and dmrt1 as candidate chromosome 9 gene. *Cancer Res.* 2006, 66, 290–302. [CrossRef]

62. Looijenga, L.H.; Hersmus, R.; Stoop, H.J.; van Gurp, R.J.; Veltman, J.; Beverloo, H.B.; van Drunen, E.; van Kessel, A.G.; et al. Genomic and expression profiling of human spermatocytic seminomas: Primary spermatocyte as tumorigenic precursor and dmrt1 as candidate chromosome 9 gene. *Cancer Res.* 2006, 66, 290–302. [CrossRef] [PubMed]

63. Lombardi, M.; Valli, M.; Brisigotti, M.; Rosai, J. Spermatocytic seminoma: Review of the literature and description of a new case of the anaplastic variant. *Int. J. Surg. Pathol.* 2011, 19, 5–10. [CrossRef]

64. Giannoulatou, E.; McVean, G.; Taylor, I.B.; McGowan, S.J.; Maher, G.J.; Iqbal, Z.; Pfeifer, S.P.; Turner, I.; Burkitt Wright, E.M.; Shorto, J.; et al. Contributions of intrinsic mutation rate and selfish selection to levels of de novo hras mutations in the paternal germline. *Proc. Natl. Acad. Sci. USA* 2013, 110, 20152–20157. [CrossRef] [PubMed]

65. Kao, C.S.; Badve, S.S.; Ulbright, T.M. The utility of immunostaining for nut, gage7 and ny-eso-1 in the diagnosis of spermatocytic seminoma. *Histopathology* 2014, 65, 35–44. [CrossRef] [PubMed]

66. Gentile, G.; Giunchi, F.; Schiavina, R.; Franceschelli, A.; Borghesi, M.; Zukerman, Z.; Cevenini, M.; Vagnoni, V.; Romagnoli, D.; Colombo, F.; et al. First case of bilateral, synchronous anaplastic variant of spermatocytic seminoma treated with radical orchifunicolectomy as single approach: Case report and review of the literature. *Arch. Ital. Urol. Androl.* 2014, 86, 41–42. [CrossRef] [PubMed]

67. Giannoulatou, E.; Maher, G.J.; Ding, Z.; Gillis, A.J.M.; Dorssers, L.C.J.; Hoischen, A.; Rajpert-De Meyts, E.; Consortium, W.G.S; McVean, G.; Wilkie, A.O.M.; et al. Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. *PLoS ONE* 2017, 12, e0178169. [CrossRef] [PubMed]

68. Menon, S.; Karpate, A.; Desai, S. Spermatocytic seminoma with rhabdomyosarcomatous differentiation: A case report with a review of the literature. *J. Cancer Res. Ther.* 2009, 5, 213–215.
88. Hersmus, R.; Kalfa, N.; de Leeuw, B.; Stoop, H.; Oosterhuis, J.W.; de Krijger, R.; Wolffenbuttel, K.P.; Drop, S.L.; Veitia, R.A.; Fellous, M.; et al. Foxl2 and sox9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (dsd). J. Pathol. 2008, 215, 31–38. [CrossRef] [PubMed]

89. Audi, L.; Ahmed, S.F.; Krone, N.; Cools, M.; McElreavey, K.; Holterhus, P.M.; Greenfield, A.; Bashamboo, A.; Hiort, O.; Wudy, S.A.; et al. Genetics in endocrinology: Approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (dsd): Position paper of eu cost action bm 1303 ‘dsdnet’. Eur. J. Endocrinol. 2018, 179, R197–R206. [CrossRef] [PubMed]

90. Spoor, J.A.; Oosterhuis, J.W.; Hersmus, R.; Biermann, K.; Wolffenbuttel, K.P.; Cools, M.; Kazmi, Z.; Ahmed, S.F.; Looijenga, L.H.J. Histological assessment of gonads in dsd: Relevance for clinical management. Sex. Dev. 2018, 12, 106–122. [CrossRef]

91. Dal Cin, P.; Drochmans, A.; Moerman, P.; Van den Berghe, H. Isochromosome 12p in mediastinal germ cell tumor. Cancer Genet. Cytogenet. 1989, 42, 243–251.

92. Sung, M.T.; Macleman, G.T.; Lopez-Beltran, A.; Zhang, S.; Montironi, R.; Cheng, L. Primary mediastinal seminoma: A comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. Am. J. Surg. Pathol. 2008, 32, 146–155. [CrossRef]

93. Batool, A.; Karimi, N.; Wu, X.N.; Chen, S.R.; Liu, Y.X. Testicular germ cell tumor: A comprehensive review. Cell Mol. Life Sci. 2019, 76, 1716–1727. [CrossRef]

94. Looijenga, L.H.; Hersmus, R.; Oosterhuis, J.W.; Cools, M.; Drop, S.L.; Wolffenbuttel, K.P. Tumor risk in disorders of sex development (dsd). Best Pract Res. Clin. Endocrinol. Metab. 2007, 21, 480–495. [CrossRef]

95. Pleskacova, J.; Hersmus, R.; Oosterhuis, J.W.; Setyawati, B.A.; Faradz, S.M.; Cools, M.; Wolffenbuttel, K.P.; Lebl, J.; Drop, S.L.; Looijenga, L.H. Tumor risk in disorders of sex development. Sex. Dev. 2010, 4, 259–269. [CrossRef] [PubMed]

96. Looijenga, L.H.; Hersmus, R.; de Leeuw, B.H.; Stoop, H.; Cools, M.; Oosterhuis, J.W.; Drop, S.L.; Wolffenbuttel, K.P. Gonadal tumours and dsd. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24, 291–310. [CrossRef] [PubMed]

97. Juniarto, A.Z.; Setyawati, B.A.; Miranti, I.P.; Santosa, A.; Hersmus, R.; Stoop, H.; Cools, M.; Oosterhuis, J.W.; Drop, S.L.; Faradz, S.M.; et al. Gonadal malignancy in 13 consecutive collected patients with disorders of sex development (dsd) from semarang (indonesia). J. Clin. Pathol. 2013, 66, 198–204. [CrossRef] [PubMed]

98. Cools, M. Germ cell cancer risk in dsd patients. Ann. Endocrinol. (Paris) 2014, 75, 67–71. [CrossRef] [PubMed]

99. Looijenga, L.H.; Hersmus, R.; Biermann, K.; Hoebbeke, P.; Cools, M.; Looijenga, L.H. Gonadal dysgenesis in disorders of sex development: Diagnosis and surgical management. J. Pediatr. Urol. 2016, 12, 411–416. [CrossRef] [PubMed]

100. Lee, P.A.; Nordenström, A.; Houk, C.P.; Ahmed, S.F.; Auchus, R.; Baratz, A.; Baratz Dalke, K.; Liao, L.M.; Lin-Su, K.; Looijenga, L.H.; et al. Global disorders of sex development update since 2006: Perceptions, approach and care. Horm. Res. Paediatr. 2016, 85, 158–180. [CrossRef] [PubMed]

101. Hersmus, R.; van Bever, Y.; Wolffenbuttel, K.P.; Biermann, K.; Cools, M.; Looijenga, L.H. The biology of germ cell tumours in disorders of sex development. Clin. Genet. 2017, 91, 292–301. [CrossRef] [PubMed]

102. Wermann, H.; Stoop, H.; Gillis, A.I.; Honecker, F.; van Gurp, R.J.; Ammerpohl, O.; Richter, J.; Oosterhuis, J.W.; Bokemeyer, C.; Looijenga, L.H. Global DNA methylation in fetal human germ cells and germ cell tumours: Association with differentiation and cisplatin resistance. J. Pathol. 2010, 221, 433–442. [CrossRef]

103. Netto, G.J.; Nakai, Y.; Nakayama, M.; Jadallah, S.; Toubaji, A.; Nomura, N.; Albadine, R.; Hicks, J.L.; Epstein, J.I.; Vegnasubramanian, S.; et al. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod. Pathol. 2008, 21, 1337–1344. [CrossRef]

104. Kristensen, D.G.; Nielsen, J.E.; Jorgensen, A.; Skakkebaek, N.E.; Rajpert-De Meyts, E.; Almstrup, K. Evidence that active demethylation mechanisms maintain the genome of carcinoma in situ cells hypomethylated in the adult testis. Br. J. Cancer 2014, 110, 668–678. [CrossRef]

105. Novotny, G.W.; Belling, K.C.; Bramsen, J.B.; Nielsen, J.E.; Bork-Jensen, J.; Almstrup, K.; Sonne, S.B.; Kjems, J.; Rajpert-De Meyts, E.; Jeffers, H. Microrna expression profiling of carcinoma in situ cells of the testis. Endocr. Relat. Cancer 2012, 19, 365–379. [CrossRef] [PubMed]
106. Rajpert-De Meyts, E.; Skakkebaek, N.E. Pathogenesis of testicular carcinoma in situ and germ cell cancer: Still more questions than answers. Int. J. Androl. 2011, 34, e2–e6. [CrossRef] [PubMed]

107. Cheng, L.; Sung, M.T.; Cosso-Rocca, P.; Jones, T.D.; MacLennan, G.T.; De Jong, J.; Lopez-Beltran, A.; Montironi, R.; Looijenga, L.H. Oct4: Biological functions and clinical applications as a marker of germ cell neoplasia. J. Pathol. 2007, 211, 1–9. [CrossRef] [PubMed]

108. De Jong, J.; Looijenga, L.H. Stem cell marker oct3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit. Rev. Oncog. 2006, 12, 171–203. [CrossRef] [PubMed]

109. Looijenga, L.H.; Stoop, H.; de Leeuw, H.P.; de Gouveia Brazao, C.A.; Gillis, A.J.; van Roozendaal, K.E.; van Zoelen, E.J.; Weber, R.F.; Wolfenbuttel, K.P.; van Dekken, H.; et al. Pou5f1 (oct3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003, 63, 2244–2250. [PubMed]

110. Biermann, K.; Stoop, H.; Looijenga, L. C-kit protein expression does not discriminate neoplastic from non-neoplastic intratubular germ cells. Histopathology 2012, 60, 1017–1019. [CrossRef] [PubMed]

111. Stoop, H.; Kirkels, W.; Dohle, G.R.; Gillis, A.J.; den Bakker, M.A.; Biermann, K.; Oosterhuis, W.; Looijenga, L.H. Diagnosis of testicular carcinoma in situ ‘intratubular and microinvasive’ seminoma and embryonal carcinoma using direct enzymatic alkaline phosphatase reaction on frozen histological sections. Histopathology 2011, 58, 440–446. [CrossRef] [PubMed]

112. Stoop, H.; Honecker, F.; van de Geijn, G.J.; Gillis, A.J.; Cools, M.C.; de Boer, M.; Bokemeyer, C.; Wolfenbuttel, K.P.; Drop, S.L.; de Krijger, R.R.; et al. Stem cell factor as a novel diagnostic marker for early malignant germ cells. J. Pathol. 2008, 216, 43–54. [CrossRef] [PubMed]

113. De Jong, J.; Stoop, H.; Gillis, A.J.; van Gurp, R.J.; van de Geijn, G.J.; Boer, M.; Hersmus, R.; Saunders, P.T.; Anderson, R.A.; Oosterhuis, J.W.; et al. Differential expression of sox17 and sox2 in germ cells and stem cells has biological and clinical implications. J. Pathol. 2008, 215, 21–30. [CrossRef] [PubMed]

114. Di Vizio, D.; Cito, L.; Boccia, A.; Chieffi, P.; Insabato, L.; Pettinato, G.; Motti, M.L.; Schepis, F.; D’Amico, W.; Fabiani, F.; et al. Loss of the tumor suppressor gene pten marks the transition from intratubular germ cell neoplasias (itgcn) to invasive germ cell tumors. Oncogene 2005, 24, 1882–1894. [CrossRef] [PubMed]

115. Turnbull, C.; Rapley, E.A.; Seal, S.; Pernet, D.; Renwick, A.; Hughes, D.; Ricketts, M.; Linger, R.; Nsengimana, J.; Deloukas, P.; et al. Variants near dmr1, tert and atf7ip are associated with testicular germ cell cancer. Nat. Genet. 2010, 42, 604–607. [CrossRef] [PubMed]

116. Rapley, E.A.; Nathanson, K.L. Predisposition alleles for testicular germ cell tumour. Curr. Opin. Genet. Dev. 2010, 20, 225–230. [CrossRef] [PubMed]

117. Litchfield, K.; Loveday, C.; Levy, M.; Dudakia, D.; Rapley, E.; Nsengimana, J.; Bishop, D.T.; Reid, A.; Huddart, R.; Broderick, P.; et al. Large-scale sequencing of testicular germ cell tumour (tgct) cases excludes major tgf predisposition gene. Eur. Urol. 2018, 73, 828–831. [CrossRef] [PubMed]

118. Wang, Z.; McGlynn, K.A.; Rajpert-De Meyts, E.; Bishop, D.T.; Chung, C.C.; Dalgaard, M.D.; Greene, M.H.; Gupta, R.; Grotmol, T.; Haugen, T.B.; et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat. Genet. 2017, 49, 1141–1147. [CrossRef]

119. Litchfield, K.; Levy, M.; Orlando, G.; Loveday, C.; Law, P.J.; Migliorini, G.; Holroyd, A.; Broderick, P.; Karlsson, R.; Haugen, T.B.; et al. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat. Genet. 2017, 49, 1133–1140. [CrossRef]

120. Kanetsky, P.A.; Mitra, N.; Vardhanabhuti, S.; Li, M.; Vaughn, D.J.; Letrero, R.; Ciosek, S.L.; Doody, D.R.; Smith, L.M.; Weaver, J.; et al. Common variation in kitlg and at 5q31.3 predisposes to testicular germ cell cancer. Nat. Genet. 2019, 51, 811–815. [CrossRef]

121. Mayer, F.; Gillis, A.J.; Dinjens, W.; Oosterhuis, J.W.; Bokemeyer, C.; Looijenga, L.H. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res. 2002, 62, 2758–2760. [CrossRef]

122. Litchfield, K.; Levy, M.; Dudakia, D.; Proszek, P.; Shipley, C.; Basten, S.; Rapley, E.; Bishop, D.T.; Reid, A.; Huddart, R.; et al. Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nat. Commun. 2016, 7, 13840. [CrossRef]

123. Deloukas, P.; Wolfenbuttel, K.P.; Hersmus, R.; Mendonca, B.B.; Karpová, J.; Drop, S.L.S.; Stoop, H.; Gillis, A.J.M.; Oosterhuis, J.W.; Costa, E.M.F.; et al. Malignant testicular germ cell tumors in postpubertal individuals with androgen insensitivity: Prevalence, pathology and relevance of single nucleotide polymorphism-based susceptibility profiling. Hum. Reprod. 2017, 32, 2561–2573. [CrossRef]

124. Atkin, N.B.; Baker, M.C. Specific chromosome change, i(12p), in testicular tumours? Lancet 1982, 2, 1349. [CrossRef]
125. Van Echten, J.; Oosterhuis, J.W.; Looijenga, L.H.; van de Pol, M.; Wiersema, J.; te Meerman, G.J.; Schaffordt Koops, H.; Sleijfer, D.T.; de Jong, B. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. *Genes Chromosomes Cancer* **1995**, *14*, 133–144. [CrossRef] [PubMed]

126. Mostert, M.M.; van de Pol, M.; Olde Weghuis, D.; Suijkerbuijk, R.F.; Geurts van Kessel, A.; van Echten, J.; Oosterhuis, J.W.; Looijenga, L.H. Comparative genomic hybridization of germ cell tumors of the adult testis: Confirmation of karyotypic findings and identification of a 12p-amplicon. *Cancer Genet. Cytogenet.* **1996**, *89*, 146–152. [CrossRef]

127. Zafarana, G.; Gillis, A.J.; van Gurp, R.J.; Olsson, P.G.; Elstrod, F.; Stoop, H.; Millán, J.L.; Oosterhuis, J.W.; Looijenga, L.H. Coamplification of dad-r, sox5, and eki1 in human testicular seminomas, with specific overexpression of dad-r, correlates with reduced levels of apoptosis and earlier clinical manifestation. *Cancer Res.* **2002**, *62*, 1822–1831. [PubMed]

128. Clark, A.T.; Rodriguez, R.T.; Bodnar, M.S.; Abeyta, M.J.; Cedars, M.I.; Turek, P.J.; Firpo, M.T.; Firpo, M.; Reijo Pera, R.A. Human stellar, nanog, and gdf3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. *Stem Cells* **2004**, *22*, 169–179. [CrossRef] [PubMed]

129. Rosenberg, C.; Van Gurp, R.J.; Geelen, E.; Oosterhuis, J.W.; Looijenga, L.H. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. *Oncogene* **2000**, *19*, 5858–5862. [CrossRef] [PubMed]

130. Dorssers, L.C.J.; Gillis, A.J.M.; Stoop, H.; van Marion, R.; Nieboer, M.M.; van Riet, J.; van der Werken, H.J.G.; Oosterhuis, J.W.; de Ridder, J.; Looijenga, L.H.J. Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development. *Br. J. Cancer* **2019**, *120*, 444–452. [CrossRef] [PubMed]

131. McIntyre, A.; Summersgill, B.; Jafer, O.; Rodriguez, S.; Zafarana, G.; Oosterhuis, J.W.; Gillis, A.J.; Looijenga, L.; Cooper, C.; Huddart, R.; et al. Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cdna clones. *Oncogene* **2004**, *23*, 9142–9147. [CrossRef]

132. Zafarana, G.; Grygalewicz, B.; Gillis, A.J.; Vissers, L.E.; van de Vliet, W.; van Gurp, R.J.; Stoop, H.; Debiec-Rychter, M.; Oosterhuis, J.W.; van Kessel, A.G.; et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array cgh. *Cancer Genet. Cytogenet.* **2003**, *147*, 146–152. [CrossRef]

133. Looijenga, L.H.; Zafarana, G.; Grygalewicz, B.; Summersgill, B.; Debiec-Rychter, M.; Veltman, J.; Schoennakers, E.F.; Rodriguez, S.; Jafer, O.; Clark, J.; et al. Role of gain of 12p in germ cell tumour development. *APMIS* **2003**, *111*, 161–171, discussion 172–163. [CrossRef]

134. Roeofs, H.; Mostert, M.C.; Pompe, K.; Zafarana, G.; van Oorschot, M.; van Gurp, R.J.; Gillis, A.J.; Stoop, H.; Beverloo, B.; Oosterhuis, J.W.; et al. Restricted 12p amplification and ras mutation in human germ cell tumors of the adult testis. *Am. J. Pathol.* **2000**, *157*, 1155–1166. [CrossRef]

135. Shen, H.; Shih, J.; Hollern, D.P.; Wang, L.; Bowlby, R.; Tickoo, S.K.; Thorisson, V.; Mungall, A.J.; Newton, Y.; Hegde, A.M.; et al. Integrated molecular characterization of testicular germ cell tumors. *Cell Rep.* **2018**, *23*, 3392–3406. [CrossRef] [PubMed]

136. Rodriguez, S.; Jafer, O.; Goker, H.; Summersgill, B.M.; Zafarana, G.; Gillis, A.J.; van Gurp, R.J.; Oosterhuis, J.W.; Lu, Y.J.; Huddart, R.; et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. *Oncogene* **2003**, *22*, 1880–1891. [CrossRef] [PubMed]

137. Litchfield, K.; Summersgill, B.; Yost, S.; Sultana, R.; Labreche, K.; Dudakia, D.; Renwick, A.; Seal, S.; Al-Saadi, R.; Broderick, P.; et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. *Nat. Commun.* **2015**, *6*, 5973. [CrossRef] [PubMed]

138. Taylor-Wéiner, A.; Zack, T.; O’Donnell, E.; Guerrero, J.L.; Bernard, B.; Reddy, A.; Han, G.C.; AlDubayan, S.; Amin-Mansour, A.; Schumacher, S.E.; et al. Genomic evolution and chemoresistance in germ-cell tumours. *Nature* **2016**, *540*, 114–118. [CrossRef] [PubMed]

139. Cutcutache, I.; Suzuki, Y.; Tan, I.B.; Ramgopal, S.; Zhang, S.; Ramnarayanan, K.; Gan, A.; Lee, H.H.; Tay, S.T.; Ooi, A.; et al. Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas. *Eur. Urol.* **2015**, *68*, 77–83. [CrossRef] [PubMed]

140. Wang, L.; Yamaguchi, S.; Burstein, M.D.; Terashima, K.; Chang, K.; Ng, H.K.; Nakamura, H.; He, Z.; Dodapaneni, H.; Lewis, L.; et al. Novel somatic and germline mutations in intracranial germ cell tumours. *Nature* **2014**, *511*, 241–245. [CrossRef]
141. Goddard, N.C.; McIntyre, A.; Summersgill, B.; Gilbert, D.; Kitazawa, S.; Shipley, J. Kit and ras signalling pathways in testicular germ cell tumours: New data and a review of the literature. *Int. J. Androl.* 2007, 30, 337–348, discussion 349. [CrossRef]

142. McIntyre, A.; Summersgill, B.; Grygalewicz, B.; Gillis, A.J.; Stoop, J.; van Gurp, R.J.; Dennis, N.; Fisher, C.; Huddart, R.; Cooper, C.; et al. Amplification and overexpression of the kit gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. *Cancer Res.* 2005, 65, 8085–8089. [CrossRef]

143. Samaniego, F.; Rodriguez, E.; Houldsworth, J.; Murty, V.V.; Ladanyi, M.; Lele, K.P.; Chen, Q.G.; Dmitrovsky, E.; Geller, N.L.; Reuter, V.; et al. Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification. *Genes Chromosomes Cancer* 1999, 1, 289–300. [CrossRef]

144. Rijlaarsdam, M.A.; Rijlaarsdam, D.J.; Gillis, A.J.; Dorssers, L.C.; Looijenga, L.H. Mimsg: A target enrichment algorithm for predicted mir-mrna interactions based on relative ranking of matched expression data. *Bioinformatics* 2013, 29, 1638–1646. [CrossRef]

145. Bagrodia, A.; Lee, B.H.; Lee, W.; Cha, E.K.; Sfakianos, J.P.; Iyer, G.; Pietzak, E.J.; Gao, S.P.; Zabor, E.C.; Ostrovnaya, I.; et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. *J. Clin. Oncol.* 2016, 34, 4000–4007. [CrossRef] [PubMed]

146. Bauer, S.; Muhlenberg, T.; Mayer, F.; Gillis, A.J.; Stoop, J.; van Gurp, R.J.; Dennis, N.; Fisher, C.; Kitazawa, S.; Shipley, J.; Gauler, T.; Schuler, M.; Looijenga, L. Therapeutic potential of mdm2 inhibition in malignant germ cell tumours. *Eur. Urol.* 2010, 57, 679–687. [CrossRef] [PubMed]

147. Koster, R.; Timmer-Bosscha, H.; Bischoff, R.; Gietema, J.A.; de Jong, S. Disruption of the mdm2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the fas/ fasl pathway. *Cell Death Dis.* 2011, 2, e148. [CrossRef] [PubMed]

148. Honecker, F.; Wermann, H.; Mayer, F.; Gillis, A.J.; Stoop, H.; van Gurp, R.J.; Oechsle, K.; Steyerberg, E.; Hartmann, J.T.; Dinjens, W.N.; et al. Microsatellite instability, mismatch repair deficiency, and braf mutation in treatment-resistant germ cell tumors. *J. Clin. Oncol.* 2009, 27, 2129–2136. [CrossRef] [PubMed]

149. Looijenga, L.H.; Oosterhuis, J.W. Pathobiology of testicular germ cell tumors: Views and news. *Anal. Quant. Cytol. Histol.* 2002, 24, 263–279.

150. Cools, M.; Wolff enbuttel, K.P.; Drop, S.L.; Oosterhuis, J.W.; Looijenga, L.H. Gonadal development and tumor formation at the crossroads of male and female sex determination. *Sex. Dev.* 2011, 5, 167–180. [CrossRef] [PubMed]

151. Van Der Zwan, Y.G.; Stoop, H.; Rossello, F.; White, S.J.; Looijenga, L.H. Role of epigenetics in the etiology of germ cell cancer. *Int. J. Dev. Biol.* 2013, 57, 299–308. [CrossRef]

152. Looijenga, L.H.; Van Agthoven, T.; Biermann, K. Development of malignant germ cells—the genenvironmental hypothesis. *Int. J. Dev. Biol.* 2013, 57, 241–253. [CrossRef]

153. Rijlaarsdam, M.A.; Looijenga, L.H. An oncofetal and developmental perspective on testicular germ cell tumors. *Cytol. Histol.* 2014, 29, 59–74. [CrossRef]

154. Lobo, J.; Gillis, A.J.M.; Jeronimo, C.; Henrique, R.; Looijenga, L.H.J. Human germ cell tumors are developmental cancers: Impact of epigenetics on pathobiology and clinic. *Int. J. Mol. Sci.* 2019, 20, 258. [CrossRef]

155. Honorio, S.; Agathanggelou, A.; Wernert, N.; Rothe, M.; Maher, E.R.; Latif, F. Frequent epigenetic inactivation of the rassf1a tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. *Oncogene* 2003, 22, 461–466. [CrossRef]

156. Looijenga, L.H.; Gillis, A.J.; van Gurp, R.J.; Verkerk, A.J.; Oosterhuis, J.W. X inactivation in human testicular germ cell tumors. *Am. J. Pathol.* 1997, 151, 581–590.

157. Kawakami, T.; Okamoto, K.; Ogawa, O.; Okada, Y. Xist unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. *Lancet* 2004, 363, 40–42. [CrossRef]

158. Voorhoeve, P.M.; le Sage, C.; Schrier, M.; Gillis, A.J.; Stoop, H.; Nagel, R.; Liu, Y.P.; van Duijse, J.; Drost, J.; Griekspoor, A.; et al. A genetic screen implicates mirna-372 and mirna-373 as oncogenes in testicular germ cell tumors. *Cell* 2006, 124, 1169–1181. [CrossRef] [PubMed]

159. Bae, Y.U.; Son, Y.; Kim, C.H.; Kim, K.S.; Hyun, S.H.; Woo, H.G.; Jee, B.A.; Choi, J.H.; Sung, H.K.; Choi, H.C.; et al. Embryonic stem cell-derived mmu-mir-291a-3p inhibits cellular senescence in human dermal fibroblasts through the tgf–receptor 2 pathway. *J. Gerontol. A Biol. Sci. Med. Sci.* 2019, 74, 1359–1367. [CrossRef] [PubMed]
160. Gillis, A.J.; Stoop, H.J.; Hersmus, R.; Oosterhuis, J.W.; Sun, Y.; Chen, C.; Guenther, S.; Sherlock, J.; Veltman, I.; Baeten, J.; et al. High-throughput microRNAome analysis in human germ cell tumours. *J. Pathol.* 2007, 213, 319–328. [CrossRef] [PubMed]

161. Rijlaarsdam, M.A.; van Agthoven, T.; Gillis, A.J.; Patel, S.; Hayashibara, K.; Lee, K.Y.; Looijenga, L.H. Identification of known and novel germ cell cancer-specific (embryonic) mirs in serum by high-throughput profiling. *Andrology* 2015, 3, 85–91. [CrossRef] [PubMed]

162. Vilela-Salgueiro, B.; Barros-Silva, D.; Lobo, J.; Costa, A.L.; Guimaraes, R.; Cantante, M.; Lopes, P.; Braga, I.; Oliveira, J.; Henrique, R.; et al. Germ cell tumour subtypes display differential expression of microRNA371a-3p. *Philos. Trans. R Soc. Lond B Biol. Sci.* 2018, 373. [CrossRef]

163. Gillis, A.J.; Rijlaarsdam, M.A.; Eini, R.; Dorssers, L.C.; Biermann, K.; Murray, M.J.; Nicholson, J.C.; Coleman, N.; Dieckmann, K.P.; Belge, G.; et al. Targeted serum microRNA (tsmir) test for diagnosis and follow-up of (testicular) germ cell cancer patients: A proof of principle. *Mol. Oncol.* 2013, 7, 1083–1092. [CrossRef]

164. Murray, M.J.; Bell, E.; Raby, K.L.; Rijlaarsdam, M.A.; Gillis, A.J.; Looijenga, L.H.; Brown, H.; Destenaves, B.; Nicholson, J.C.; Coleman, N. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. *Br. J. Cancer* 2016, 114, 151–162. [CrossRef]

165. Murray, M.J.; Coleman, N. Testicular cancer: A new generation of biomarkers for malignant germ cell tumours. *Nat. Rev. Urol.* 2012, 9, 298–300. [CrossRef] [PubMed]

166. Léao, R.; van Agthoven, T.; Figueiredo, A.; Jewett, M.A.S.; Fadaak, K.; Sweet, J.; Ahmad, A.E.; Anson-Cartwright, L.; Chung, P.; Hansen, A.; et al. Serum mirna predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor. *J. Urol.* 2018, 200, 126–135. [CrossRef] [PubMed]

167. Mego, M.; van Agthoven, T.; Gronesova, P.; Chovanec, M.; Miskovska, V.; Mardiak, J.; Looijenga, L.H.J. Clinical utility of plasma mir-371a-3p in germ cell tumors. *J. Cell Mol. Med.* 2019, 23, 1128–1136. [PubMed]

168. Salvatori, D.C.F.; Dorssers, L.C.J.; Gillis, A.J.; Looijenga, L.H.; Brown, H.; Destenaves, B.; Nicholson, J.C.; Coleman, N. A novel and specific plasma biomarker panel for monitoring undifferentiated and potentially malignant human pluripotent stem cells in teratoma assays. *Stem Cell Rep.* 2018, 11, 1493–1505. [CrossRef] [PubMed]

169. Van Agthoven, T.; Eijkenboom, W.M.H.; Looijenga, L.H.J. MicroRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. *Cell Oncol.* 2017, 40, 379–388. [CrossRef] [PubMed]

170. Van Agthoven, T.; Looijenga, L.H. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (amptsmir test). *Oncotarget* 2016, 8, 58037–58049. [CrossRef]

171. Spiekermann, M.; Belge, G.; Winter, N.; Ikogho, R.; Balks, T.; Bullerdiek, J.; Dieckmann, K.P. MicroRNA mir-371a-3p in serum of patients with germ cell tumours: Evaluations for establishing a serum biomarker. *Andrology* 2015, 3, 78–84. [CrossRef] [PubMed]

172. Dieckmann, K.P.; Spiekermann, M.; Balks, T.; Ikogho, R.; Anheuser, P.; Wosniok, W.; Loening, T.; Bullerdiek, J.; Belge, G. MicroRNA mir-371a-3p—A novel serum biomarker of testicular germ cell tumors: Evidence for specificity from measurements in testicular vein blood and in neoplastic hydrocele fluid. *Urol. Int.* 2016, 97, 76–83. [CrossRef]

173. Flor, I.; Spiekermann, M.; Loning, T.; Dieckmann, K.P.; Belge, G.; Bullerdiek, J. Expression of microRNAs of c19mr in different histological types of testicular germ cell tumour. *Cancer Genomics Proteomics* 2016, 13, 281–289.

174. Dieckmann, K.P.; Radtke, A.; Spiekermann, M.; Balks, T.; Matthies, C.; Becker, P.; Ruf, C.; Ong, C.; Oechsle, K.; Bokemeyer, C.; et al. Serum levels of microRNA mir-371a-3p: A sensitive and specific new biomarker for germ cell tumours. *Eur. Urol.* 2017, 71, 213–220. [CrossRef]
175. Dieckmann, K.P.; Radtke, A.; Geczi, L.; Matthies, C.; Anheuser, P.; Eckardt, U.; Sommer, J.; Zengerling, F.; Trenti, E.; Pichler, R.; et al. Serum levels of microrna-371a-3p (m371 test) as a new biomarker of testicular germ cell tumors: Results of a prospective multicentric study. *J. Clin. Oncol.* 2019, 37, 1412–1423. [CrossRef] [PubMed]

176. Boellaard, W.P.A.; Gillis, A.J.M.; van Leenders, G.; Stoop, H.; van Agthoven, T.; Dorssers, L.C.J.; Dinkelman-Smit, M.; Boormans, J.L.; Looijenga, L.H.J. Cellular origin of microrna-371a-3p in healthy males based on systematic urogenital tract tissue evaluation. *Andrology* 2019, 7, 463–468. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).